Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(0.94) by 35.11 percent. This is a 284.85 percent decrease over losses of $(0.33) per share from the same period last year.